Literature DB >> 16359925

Worldwide burden of gynaecological cancer: the size of the problem.

R Sankaranarayanan1, J Ferlay.   

Abstract

The estimation of cancer burden is valuable to set up priorities for disease control. The comprehensive global cancer statistics from the International Agency for Research on Cancer indicate that gynaecological cancers accounted for 19% of the 5.1 million estimated new cancer cases, 2.9 million cancer deaths and 13 million 5-year prevalent cancer cases among women in the world in 2002. Cervical cancer accounted for 493 000 new cases and 273 000 deaths; uterine body cancer for 199 000 new cases and 50 000 deaths; ovarian cancer for 204 000 new cases and 125 000 deaths; cancers of the vagina, vulva and choriocarcinoma together constituted 45 900 cases. More than 80% of the cervical cancer cases occurred in developing countries and two-thirds of corpus uteri cases occurred in the developed world. Political will and advocacy to invest in healthcare infrastructure and human resources to improve service delivery and accessibility are vital to reduce the current burden in low- and medium-resource countries.

Entities:  

Mesh:

Year:  2005        PMID: 16359925     DOI: 10.1016/j.bpobgyn.2005.10.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  185 in total

1.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Knowledge and health care-seeking behavior in relation to gynecological malignancies in India: a study of the patients with gynecological malignancies in a tertiary care hospital of Kolkata.

Authors:  Madhutandra Sarkar; Hiralal Konar; D K Raut
Journal:  J Cancer Educ       Date:  2011-06       Impact factor: 2.037

3.  E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Authors:  Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  Wine drinking and epithelial ovarian cancer risk: a meta-analysis.

Authors:  Hee Seung Kim; Jae Weon Kim; Leo J Shouten; Susanna C Larsson; Hyun Hoon Chung; Yong Beom Kim; Woong Ju; Noh Hyun Park; Yong Sang Song; Seung Cheol Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

5.  Immigrant women's experiences and views on the prevention of cervical cancer: a qualitative study.

Authors:  Maria Grandahl; Tanja Tydén; Maria Gottvall; Ragnar Westerling; Marie Oscarsson
Journal:  Health Expect       Date:  2012-12-16       Impact factor: 3.377

6.  Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.

Authors:  Ling Liu; Jing Zou; Qi Wang; Fu-Qiang Yin; Wei Zhang; Li Li
Journal:  Tumour Biol       Date:  2014-05-08

7.  Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis.

Authors:  Shanliang Zhong; Lin Chen; Mengmeng Lv; Tengfei Ma; Xiaohui Zhang; Jianhua Zhao
Journal:  Tumour Biol       Date:  2014-08-06

8.  Requirement for stromal estrogen receptor alpha in cervical neoplasia.

Authors:  Sang-Hyuk Chung; Myeong Kyun Shin; Kenneth S Korach; Paul F Lambert
Journal:  Horm Cancer       Date:  2012-10-13       Impact factor: 3.869

Review 9.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  Characterization of Molecular Markers Indicative of Cervical Cancer Progression.

Authors:  Hilal Arnouk; Mark A Merkley; Robert H Podolsky; Hubert Stöppler; Carlos Santos; Manuel Alvarez; Julio Mariategui; Daron Ferris; Jeffrey R Lee; William S Dynan
Journal:  Proteomics Clin Appl       Date:  2009-05-05       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.